Skip to main content

Judit Vico Romero

Institutions of which they are part

Research technician
Liver Diseases
Vall Hebron Institut de Recerca

Judit Vico Romero

Institutions of which they are part

Research technician
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Maria Buti Ferret, Montserrat Gomez Perez, Judit Romero Vico, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 30/06/2025

Immune profiling to guide host-directed interventions to cure HBV infections

IP: Maria Buti Ferret
Collaborators: Tamara Del Rio Higueras, Mª Eulàlia Molinas Guilera, Amaia Latasa Arrazubi, Judit Romero Vico, Immune profiling to guide host-directed interventions to cure HBV infections, Maria del Mar Riveiro Barciela
Funding agency: EUROPEAN COMMISSION
Funding: 211443.8
Reference: IP-CURE-B_H2020SC1BHC2019
Duration: 01/01/2020 - 31/12/2025

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Roser Navarro García

Roser Navarro García

Infectious Diseases
Read more
Mª Carmen López  Arribas

Mª Carmen López Arribas

Research technician
Molecular Medical Imaging
Read more
Jesús Francisco Lopez Lozano

Jesús Francisco Lopez Lozano

Read more
Jorge Serra Pueyo

Jorge Serra Pueyo

Main researcher
Physiology and Pathophysiology of the Digestive Tract
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.